secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANGIODYNAMICS INC (ANGO)
CIK:        0001275187
Form:       8-K
Filed at:   2025-01-08T23:59:59+00:00
Accession:  0001140361-25-000535
Event type: earnings
Sentiment:  positive
Materiality: 0.78
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AngioDynamics Q2 pro forma sales up 9.2% to $73.0M; raises FY25 EBITDA guidance to $1-3M
--------------------------------------------------------------------------------

- Pro forma net sales $73.0M (+9.2% YoY); Med Tech $31.5M (+25%) led by AngioVac (+50.7%), Auryon (+21.8%), AlphaVac (+33.3%), NanoKnife disposables (+23.1%).
- GAAP net loss $10.7M ($0.26 loss/share); adjusted loss $0.04/share vs $0.08 loss prior year.
- Adjusted EBITDA $3.1M (vs $0.0M); FY25 guidance raised to $1-3M from loss of $2.5M-$0; adjusted loss per share guidance improved to $0.34-0.38.
- Received FDA 510(k) clearance for NanoKnife prostate tissue ablation and CPT Category I codes for IRE (effective Jan 2026).
- Cash $54.1M; operating cash flow $2.5M; $1.1M used on share repurchases in Q2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1275187/000114036125000535/0001140361-25-000535-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1275187/000114036125000535/ef20041243_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-000535

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer